PDF(Pubmed)
Abstract：
UNASSIGNED: Metastatic spinal lesions are a significant cause of morbidity and decreased quality of life in those with a high tumor burden. Despite treatment modalities such as medical therapy (e.g., chemotherapy, steroids), spinal augmentation procedures, and radiation therapy, many patients still experience refractory back pain due to neoplastic infiltration of the vertebral body and/or pathologic compression fractures. With the aim to address refractory pain in patients who have exhausted conventional treatment options, Stryker developed the OptablateTM Bone Tumor Ablation system (BTA; Stryker Corporation, Kalamazoo, MI), which delivers radiofrequency energy to pathologic vertebral body lesions. In this preliminary single-institution study, we characterize the use of the BTA system in 11 patients undergoing kyphoplasty for pathologic spinal lesions with the goal to demonstrate the impact of this novel technology on refractory pain in this challenging clinical setting.
UNASSIGNED: A single-center retrospective chart review was performed on all patients identified as those receiving tumor ablation/kyphoplasty for spinal neoplasms using the OptablateTM BTA system performed by a single surgeon at the University of Oklahoma Medical Center. Sex, age, primary lesion type, presenting symptomatology, spinal level, time of follow-up, and outcome were obtained from the electronic medical record (EMR).
UNASSIGNED: Eleven patients (4 males, 7 females) with a mean age of 62 (range, 38-82) years had an average follow-up time of 6 months. Presenting symptoms attributed to spinal pathology included back pain (n = 11, 100%), pathologic fracture (n = 6, 55%), and lower extremity weakness (n = 3, 27%). A total of 20 lesions were ablated at 12 vertebral levels. Eight patients (73%) had improved pain. No complications were reported.
UNASSIGNED: This preliminary study documents the safety of the BTA system, in addition to its diverse use across many levels. The majority of patients reported improvement in their pain. Further study is required to fully characterize the use of the BTA system in those with neoplastic spinal pathology.
UNASSIGNED: A single-center retrospective chart review was performed on all patients identified as those receiving tumor ablation/kyphoplasty for spinal neoplasms using the OptablateTM BTA system performed by a single surgeon at the University of Oklahoma Medical Center. Sex, age, primary lesion type, presenting symptomatology, spinal level, time of follow-up, and outcome were obtained from the electronic medical record (EMR).
UNASSIGNED: Eleven patients (4 males, 7 females) with a mean age of 62 (range, 38-82) years had an average follow-up time of 6 months. Presenting symptoms attributed to spinal pathology included back pain (n = 11, 100%), pathologic fracture (n = 6, 55%), and lower extremity weakness (n = 3, 27%). A total of 20 lesions were ablated at 12 vertebral levels. Eight patients (73%) had improved pain. No complications were reported.
UNASSIGNED: This preliminary study documents the safety of the BTA system, in addition to its diverse use across many levels. The majority of patients reported improvement in their pain. Further study is required to fully characterize the use of the BTA system in those with neoplastic spinal pathology.
摘要：
■脊柱转移性病变是高肿瘤负担患者发病和生活质量下降的重要原因。尽管采用医学治疗等治疗方式(例如，化疗,类固醇)，脊柱增强手术,和放射治疗,由于椎体肿瘤浸润和/或病理性压缩性骨折，许多患者仍然会出现难治性背痛。为了解决那些已经用尽常规治疗方案的患者的难治性疼痛，Stryker开发了OptablateTM骨肿瘤消融系统(BTA；StrykerCorporation，卡拉马祖,MI),向病理性椎体病变提供射频能量。在这项初步的单一机构研究中，我们描述了在11例接受脊柱后凸成形术治疗病理性脊柱病变的患者中使用BTA系统的情况,目的是证明在这种具有挑战性的临床环境中,这项新技术对难治性疼痛的影响.
在俄克拉荷马大学医学中心的一名外科医生使用OptablateTMBTA系统，对所有确定为接受肿瘤消融/椎体后凸成形术治疗脊柱肿瘤的患者进行单中心回顾性图表回顾。性,年龄,原发病变类型,呈现症状学，脊柱水平,随访时间,结果来自电子病历（EMR）。
■11名患者（4名男性，7名女性)，平均年龄62岁(范围，38-82）年的平均随访时间为6个月。出现的症状归因于脊柱病理包括背痛（n=11，100％），病理性骨折（n=6，55%），和下肢无力（n=3，27％）。在12个椎骨水平上总共消融了20个病变。8例患者（73%）疼痛改善。无并发症报告。
■这项初步研究记录了BTA系统的安全性，除了它在许多层面的不同用途。大多数患者报告疼痛有所改善。需要进一步的研究来充分表征BTA系统在肿瘤脊柱病理学患者中的使用。
在俄克拉荷马大学医学中心的一名外科医生使用OptablateTMBTA系统，对所有确定为接受肿瘤消融/椎体后凸成形术治疗脊柱肿瘤的患者进行单中心回顾性图表回顾。性,年龄,原发病变类型,呈现症状学，脊柱水平,随访时间,结果来自电子病历（EMR）。
■11名患者（4名男性，7名女性)，平均年龄62岁(范围，38-82）年的平均随访时间为6个月。出现的症状归因于脊柱病理包括背痛（n=11，100％），病理性骨折（n=6，55%），和下肢无力（n=3，27％）。在12个椎骨水平上总共消融了20个病变。8例患者（73%）疼痛改善。无并发症报告。
■这项初步研究记录了BTA系统的安全性，除了它在许多层面的不同用途。大多数患者报告疼痛有所改善。需要进一步的研究来充分表征BTA系统在肿瘤脊柱病理学患者中的使用。
